Rice bran in ready-to-use therapeutic foods for microbiota-targeted treatment of childhood malnutrition

即用型治疗食品中的米糠用于针对儿童营养不良的微生物群治疗

基本信息

  • 批准号:
    10750478
  • 负责人:
  • 金额:
    $ 41.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-18 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Severe acute malnutrition (SAM) is the cause for nearly half of all child deaths under the age five. In Indonesia, SAM affects more than 2 million children and ~1% receive adequate treatment due to lack of access and coverage. Typical SAM treatment includes ready-to-use therapeutic foods (RUTF) which have shown immediate benefit and reduction in mortality rates, however, recovered children have persistent dysbiotic gut microbiota, leaving them susceptible to infection and malnutrition relapse as well as risk for chronic metabolic disease later in life. A growing focus has been placed on prebiotic foods in treatment of gut dysfunction, with little known regarding efficacy of prebiotic rich foods during SAM treatment and recovery. Rice bran contains prebiotics of growing significance to supporting favorable changes to commensal microbiota and microbiota metabolism. Rice Bran contains unique bioactive phytochemicals, lipids, and amino acids when compared to bran from other cereals. Compelling published and preliminary evidence from animals and humans support that rice bran positively influences the gut microbiome and metabolome for protection against diarrheal disease and supports healthy growth. Directed attention to improving SAM treatment of children with an innovative RUTF formulation containing rice bran is the basis for an ongoing double-blinded, randomized control trial (NCT05319717). This RCT is the first examination of rice bran during SAM treatment. The objective of this proposal is to examine whether the addition of rice bran to RUTFs results in changes to the recovering child’s microbiota and metabolism that provide enhanced protection against enteric infections, prevention of malnutrition relapse and promotion of blood metabolic profiles indicative of enhanced nutrient absorption. The hypothesis is that the RUTF + rice bran treatment will increase stool microbial diversity and favorably modulate the dried blood spot metabolome in SAM children when compared to a control RUTF. Dietary rice bran inclusion is expected to modulate both amino acid and lipid metabolism via gut microbiota in children recovered from SAM. Two proposed specific aims to explore this hypothesis are 1) Determine the effect of RUTF + rice bran on gut microbiota composition in the treatment of SAM compared to control RUTF in SAM in children ages 6-59 months and 2) Examine and establish EED marker and metabolite profiles associated with RUTF + rice bran in the treatment of SAM compared to control RUTF. Rice bran inclusion to RUTFs is anticipated to become a local, affordable solution that can enhance protection against microbial dysbiosis that is associated with malnutrition relapse, and results from stool and blood analysis will significantly advance our global knowledge of how to improve gut-directed SAM treatments.
项目摘要 严重急性营养不良是五岁以下儿童死亡的近一半原因。在 在印度尼西亚,SAM影响了200多万儿童,约1%的儿童因缺乏适当的治疗而接受治疗。 获取和覆盖。典型的SAM治疗包括即用型治疗食品(RUTF),其具有 然而,康复后的儿童仍持续受到 肠道微生物群失调,使他们容易感染和营养不良复发, 慢性代谢性疾病。益生元食品在肠道治疗中的作用越来越受到关注 在SAM治疗和恢复期间,关于富含益生元的食物的功效知之甚少。 米糠含有益生元的增长意义,以支持有利的变化, 微生物群和微生物群代谢。米糠含有独特的生物活性植物化学物质,脂质和氨基 酸相比,从其他谷物麸皮。令人信服的已发表和初步的动物证据 人类支持米糠对肠道微生物组和代谢组产生积极影响, 预防疟疾,促进健康成长。注意改善SAM治疗, 儿童与一个创新的RUTF配方含有米糠是一个正在进行的双盲, 随机对照试验(NCT 05319717)。该RCT是SAM处理期间对米糠的首次检查。 本提案的目的是研究在RUTFs中添加米糠是否会导致 恢复中的儿童的微生物群和新陈代谢提供增强的保护,防止肠道感染, 预防营养不良复发和促进指示营养增强的血液代谢谱 吸收假设RUTF +米糠处理将增加粪便微生物多样性, 当与对照RUTF相比时,有利地调节SAM儿童中的干血斑代谢组。 预期膳食米糠包含物通过肠道微生物群调节氨基酸和脂质代谢, 孩子们从SAM中恢复过来。探索这一假设的两个建议的具体目标是:1)确定 与对照RUTF相比,RUTF +米糠对SAM处理中肠道微生物群组成的影响 SAM在6-59个月的儿童和2)检查和建立EED标志物和代谢物谱 与对照RUTF相比,SAM处理中RUTF +米糠相关。米糠内含物 RUTFs预计将成为一种当地的,负担得起的解决方案,可以加强对微生物的保护, 与营养不良复发相关的生态失调,粪便和血液分析的结果将显着 推进我们对如何改善肠道导向SAM治疗的全球知识。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elizabeth P Ryan其他文献

Elizabeth P Ryan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Elizabeth P Ryan', 18)}}的其他基金

Dietary Rice Bran Phytochemicals and Microbial Metabolites for Colon Chemoprevent
用于结肠化学预防的膳食米糠植物化学物质和微生物代谢物
  • 批准号:
    8304033
  • 财政年份:
    2012
  • 资助金额:
    $ 41.66万
  • 项目类别:
Dietary Rice Bran Phytochemicals and Microbial Metabolites for Colon Chemoprevent
用于结肠化学预防的膳食米糠植物化学物质和微生物代谢物
  • 批准号:
    8517050
  • 财政年份:
    2012
  • 资助金额:
    $ 41.66万
  • 项目类别:
Probiotic Metabolism of Rice Bran Phytochemicals for Chemoprevention
米糠植物化学物质的益生菌代谢用于化学预防
  • 批准号:
    7897265
  • 财政年份:
    2010
  • 资助金额:
    $ 41.66万
  • 项目类别:
Probiotic Metabolism of Rice Bran Phytochemicals for Chemoprevention
米糠植物化学物质的益生菌代谢用于化学预防
  • 批准号:
    8053395
  • 财政年份:
    2010
  • 资助金额:
    $ 41.66万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 41.66万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了